Skip to main content
NSPR
NASDAQ Industrial Applications And Services

InspireMD Q2 Loss Widens to $14.3M; Cash Drops to $30.4M Amid Recall Fallout

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.05
Mkt Cap
$46.015M
52W Low
$0.63
52W High
$2.565
52W Position info
67% above low
Off High info
59% below high
Rel. Volume info
3.8× avg
Market data snapshot near publication time

NSPR sits 67% above its 52-week low of $0.63 on elevated volume (3.8× avg).

Summary

InspireMD reported a wider Q2 net loss of $14.3M and a cash balance of $30.4M, down sharply from year-end, as the CGuard Prime recall drove negative U.S. revenue and inventory write-downs.


Key Events · Earnings and Guidance · NSPR

  • Q2 Net Loss Widens to $14.3M

    Net loss for Q2 2026 was $14.324M, or $0.17 per share, compared to $13.151M, or $0.26 per share, in Q2 2025.

  • Recall Drives Negative U.S. Revenue

    U.S. revenue was $(351K) in Q2 2026, reflecting $734K of customer credits from the voluntary recall of the CGuard Prime 135cm delivery system, which exceeded gross U.S. product sales.

  • Gross Loss of $774K on Inventory Impairment

    Gross loss was $774K, including a $612K inventory impairment charge and $734K in customer credits, both tied to the recall.

  • Cash Position Drops to $30.4M

    Cash, cash equivalents, and marketable securities totaled $30.421M as of June 30, 2026, down from $54.211M at December 31, 2025, heightening going-concern risk.


Analysis · NSPR · Industrial Applications And Services

InspireMD's second quarter shows the financial damage from the voluntary recall of its CGuard Prime 135cm delivery system. Revenue was flat at $1.77M, but U.S. revenue turned negative due to $734K in customer credits, and gross profit swung to a $774K loss after a $612K inventory impairment. Net loss widened to $14.3M. Cash and marketable securities fell to $30.4M from $54.2M at year-end, intensifying the going-concern risk already flagged in prior filings. The company announced $9M in annual cost savings and expects FDA decisions on two products later this year, but the near-term liquidity picture is deteriorating.

At the time of this filing, NSPR was trading at $1.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $46M. The 52-week trading range was $0.63 to $2.57. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NSPR - Latest Insights

NSPR
Jul 29, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
NSPR
Jul 23, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
NSPR
Jul 02, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
NSPR
Jun 11, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
NSPR
Jun 03, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8